A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo
Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish functional blood vessels. Signaling through the vascular endothelial growth factor (VEGF) receptors is an important mediator of angiogenesis, a ha...
Saved in:
Published in | Angiogenesis (London) Vol. 12; no. 3; pp. 287 - 296 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Dordrecht
Springer Netherlands
01.09.2009
Springer Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish functional blood vessels. Signaling through the vascular endothelial growth factor (VEGF) receptors is an important mediator of angiogenesis, a hallmark of tumor growth and metastasis. Inhibition of signaling through VEGF has been clinically validated with FDA-approvals of bevacizumab, sorafenib, and suntinib. Our goal was to discover an orally available, selective VEGFR-2 inhibitor. A novel oxime, 1-{4-[6-amino-5-(methoxyimino-methyl)-pyrimidin-4-yloxy]-2-chloro-phenyl}-3-ethyl-urea (JNJ-38158471), was identified as a potent and selective inhibitor of VEGFR-2. While JNJ-38158471 shares some structure features with sorafenib, unlike sorafenib, it lacks Raf kinase activity. JNJ-38158471 inhibits VEGFR-2 (IC50 = 40 nM) and closely related tyrosine kinases, Ret (180 nM) and Kit (500 nM); it has no significant activity (>1 μM) against VEGFR-1 and VEGFR-3. At nanomolar levels, it inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay and inhibits VEGF-dependent endothelial migration. Once-daily oral dosing of JNJ-3815871 to nude mice bearing human A431, HCT116, and A375 tumors resulted in up to 90% tumor growth inhibition. Strikingly, after termination of JNJ-38158471 monotherapy-treatment of A375 xenografts, tumor growth delay was significantly prolonged up to 4 weeks. Anti-tumor efficacy correlated well with the observed dose concentrations (on a mg/kg basis) necessary to inhibit VEGF-induced corneal angiogenesis in C57BL/6J mice. In addition, the compound inhibited spontaneous polyp formation in the APC min-mouse model. These data demonstrate that JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor that may have therapeutic benefit in human malignancies. |
---|---|
AbstractList | Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish functional blood vessels. Signaling through the vascular endothelial growth factor (VEGF) receptors is an important mediator of angiogenesis, a hallmark of tumor growth and metastasis. Inhibition of signaling through VEGF has been clinically validated with FDA-approvals of bevacizumab, sorafenib, and suntinib. Our goal was to discover an orally available, selective VEGFR-2 inhibitor. A novel oxime, 1-{4-[6-amino-5-(methoxyimino-methyl)-pyrimidin-4-yloxy]-2-chloro-phenyl}-3-ethyl-urea (JNJ-38158471), was identified as a potent and selective inhibitor of VEGFR-2. While JNJ-38158471 shares some structure features with sorafenib, unlike sorafenib, it lacks Raf kinase activity. JNJ-38158471 inhibits VEGFR-2 (IC50 = 40 nM) and closely related tyrosine kinases, Ret (180 nM) and Kit (500 nM); it has no significant activity (>1 μM) against VEGFR-1 and VEGFR-3. At nanomolar levels, it inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay and inhibits VEGF-dependent endothelial migration. Once-daily oral dosing of JNJ-3815871 to nude mice bearing human A431, HCT116, and A375 tumors resulted in up to 90% tumor growth inhibition. Strikingly, after termination of JNJ-38158471 monotherapy-treatment of A375 xenografts, tumor growth delay was significantly prolonged up to 4 weeks. Anti-tumor efficacy correlated well with the observed dose concentrations (on a mg/kg basis) necessary to inhibit VEGF-induced corneal angiogenesis in C57BL/6J mice. In addition, the compound inhibited spontaneous polyp formation in the APC min-mouse model. These data demonstrate that JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor that may have therapeutic benefit in human malignancies. Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish functional blood vessels. Signaling through the vascular endothelial growth factor (VEGF) receptors is an important mediator of angiogenesis, a hallmark of tumor growth and metastasis. Inhibition of signaling through VEGF has been clinically validated with FDA-approvals of bevacizumab, sorafenib, and suntinib. Our goal was to discover an orally available, selective VEGFR-2 inhibitor. A novel oxime, 1-{4-[6-amino-5-(methoxyimino-methyl)-pyrimidin-4-yloxy]-2-chloro-phenyl}-3-ethyl-urea (JNJ-38158471), was identified as a potent and selective inhibitor of VEGFR-2. While JNJ-38158471 shares some structure features with sorafenib, unlike sorafenib, it lacks Raf kinase activity. JNJ-38158471 inhibits VEGFR-2 (IC50 = 40 nM) and closely related tyrosine kinases, Ret (180 nM) and Kit (500 nM); it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. At nanomolar levels, it inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay and inhibits VEGF-dependent endothelial migration. Once-daily oral dosing of JNJ-3815871 to nude mice bearing human A431, HCT116, and A375 tumors resulted in up to 90% tumor growth inhibition. Strikingly, after termination of JNJ-38158471 monotherapy-treatment of A375 xenografts, tumor growth delay was significantly prolonged up to 4 weeks. Anti-tumor efficacy correlated well with the observed dose concentrations (on a mg/kg basis) necessary to inhibit VEGF-induced corneal angiogenesis in C57BL/6J mice. In addition, the compound inhibited spontaneous polyp formation in the APC min-mouse model. These data demonstrate that JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor that may have therapeutic benefit in human malignancies. Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish functional blood vessels. Signaling through the vascular endothelial growth factor (VEGF) receptors is an important mediator of angiogenesis, a hallmark of tumor growth and metastasis. Inhibition of signaling through VEGF has been clinically validated with FDA-approvals of bevacizumab, sorafenib, and suntinib. Our goal was to discover an orally available, selective VEGFR-2 inhibitor. A novel oxime, 1-{4-[6-amino-5-(methoxyimino-methyl)-pyrimidin-4-yloxy]-2-chloro-phenyl}-3-ethyl-urea (JNJ-38158471), was identified as a potent and selective inhibitor of VEGFR-2. While JNJ-38158471 shares some structure features with sorafenib, unlike sorafenib, it lacks Raf kinase activity. JNJ-38158471 inhibits VEGFR-2 (IC50 = 40 nM) and closely related tyrosine kinases, Ret (180 nM) and Kit (500 nM); it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. At nanomolar levels, it inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay and inhibits VEGF-dependent endothelial migration. Once-daily oral dosing of JNJ-3815871 to nude mice bearing human A431, HCT116, and A375 tumors resulted in up to 90% tumor growth inhibition. Strikingly, after termination of JNJ-38158471 monotherapy-treatment of A375 xenografts, tumor growth delay was significantly prolonged up to 4 weeks. Anti-tumor efficacy correlated well with the observed dose concentrations (on a mg/kg basis) necessary to inhibit VEGF-induced corneal angiogenesis in C57BL/6J mice. In addition, the compound inhibited spontaneous polyp formation in the APC min-mouse model. These data demonstrate that JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor that may have therapeutic benefit in human malignancies. Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish functional blood vessels. Signaling through the vascular endothelial growth factor (VEGF) receptors is an important mediator of angiogenesis, a hallmark of tumor growth and metastasis. Inhibition of signaling through VEGF has been clinically validated with FDA-approvals of bevacizumab, sorafenib, and suntinib. Our goal was to discover an orally available, selective VEGFR-2 inhibitor. A novel oxime, 1-{4-[6-amino-5-(methoxyimino-methyl)-pyrimidin-4-yloxy]-2-chloro-phenyl}-3-ethyl-urea (JNJ-38158471), was identified as a potent and selective inhibitor of VEGFR-2. While JNJ-38158471 shares some structure features with sorafenib, unlike sorafenib, it lacks Raf kinase activity. JNJ-38158471 inhibits VEGFR-2 (IC50 = 40 nM) and closely related tyrosine kinases, Ret (180 nM) and Kit (500 nM); it has no significant activity (>1 μM) against VEGFR-1 and VEGFR-3. At nanomolar levels, it inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay and inhibits VEGF-dependent endothelial migration. Once-daily oral dosing of JNJ-3815871 to nude mice bearing human A431, HCT116, and A375 tumors resulted in up to 90% tumor growth inhibition. Strikingly, after termination of JNJ-38158471 monotherapy-treatment of A375 xenografts, tumor growth delay was significantly prolonged up to 4 weeks. Anti-tumor efficacy correlated well with the observed dose concentrations (on a mg/kg basis) necessary to inhibit VEGF-induced corneal angiogenesis in C57BL/6J mice. In addition, the compound inhibited spontaneous polyp formation in the APC min-mouse model. These data demonstrate that JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor that may have therapeutic benefit in human malignancies. |
Author | Borowski, Virna B. Greenberger, Lee M. Blevitt, Jonathan M. Li, Ronghua Butler, Jeannene Fuentes-Pesquera, Angel R. LaMontagne, Kenneth R. Huang, Shenlin Connolly, Peter J. |
Author_xml | – sequence: 1 givenname: Kenneth R. surname: LaMontagne fullname: LaMontagne, Kenneth R. email: Kenneth.lamontagne@novartis.com organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC, Novartis Pharmaceuticals Inc – sequence: 2 givenname: Jeannene surname: Butler fullname: Butler, Jeannene organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC – sequence: 3 givenname: Virna B. surname: Borowski fullname: Borowski, Virna B. organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC – sequence: 4 givenname: Angel R. surname: Fuentes-Pesquera fullname: Fuentes-Pesquera, Angel R. organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC – sequence: 5 givenname: Jonathan M. surname: Blevitt fullname: Blevitt, Jonathan M. organization: Department of Immunology, Johnson & Johnson Pharmaceutical Research & Development, LLC – sequence: 6 givenname: Shenlin surname: Huang fullname: Huang, Shenlin organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC – sequence: 7 givenname: Ronghua surname: Li fullname: Li, Ronghua organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC – sequence: 8 givenname: Peter J. surname: Connolly fullname: Connolly, Peter J. organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC – sequence: 9 givenname: Lee M. surname: Greenberger fullname: Greenberger, Lee M. organization: Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21997401$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19544081$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc-KFDEQxoOsuLOrD-BFgiBebE3S6U73cVn8Bwte9Byq09XTWTPJmKRnmUfxbU0zgwuCp0qqfvnqI98VufDBIyEvOXvPGVMfEmeyaSvG-qrnDa_UE7LhjaorJVh_QTasb_uq7RW7JFcp3bMCtp18Ri5530jJOr4hv2_obLezO9KEDk22B3xHQwRXOoMNcADrYHCleYBkFgeRoh9DntFZcHQbw0Oe6QQmh0gjGtyXQyVoPsaQrEf603pISK2f7WBXaIZE9yGjzxTWfTYfy5SWGgMFP54uh_CcPJ3AJXxxrtfkx6eP32-_VHffPn-9vbmrjGzbXI3AYJRMtbxGMw5dXQ_NxLtRNlMrayYEqrpRaHrGRjGBqFmn6kkaBR0KhU19Td6edPcx_FowZb2zyaBz4DEsSataspYroQr5-h_yPizRF3NacC5XC7xA_ASZ8gEp4qT30e4gHjVnek1Nn1LTJQy9pqZX4Vdn4WXY4fj44hxTAd6cgRICuCmCNzb95QTveyXZyokTl8rIbzE-Ovz_9j8IW7M9 |
CODEN | AGIOFT |
CitedBy_id | crossref_primary_10_1016_j_bmcl_2011_01_053 crossref_primary_10_1007_s00204_021_03098_w crossref_primary_10_3390_biom11060777 crossref_primary_10_1021_cb2003175 crossref_primary_10_1134_S1070428020020219 crossref_primary_10_2174_0929867327666200224102309 crossref_primary_10_2174_1871520618666180717125906 |
Cites_doi | 10.1016/j.bbrc.2008.07.121 10.1158/1078-0432.CCR-06-2844 10.1038/nrd2541 10.1016/j.cellsig.2007.05.013 10.1097/00000658-197203000-00014 10.1124/mol.104.000638 10.1006/bbrc.1995.2832 10.1038/nm0195-27 10.1038/nm0603-669 10.1002/ijc.20012 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.0.CO;2-O 10.1158/0008-5472.CAN-05-2001 10.1016/0092-8674(93)90573-9 10.1634/theoncologist.12-6-713 10.1056/NEJMoa032691 10.1016/0006-291X(89)92678-8 10.1073/pnas.95.7.3609 10.1074/jbc.275.14.10661 10.1074/jbc.M002016200 10.1074/jbc.M103130200 10.1038/35025220 10.1074/jbc.273.46.30336 10.1038/nrc2559 10.1007/s001099900019 10.1093/emboj/18.2.363 10.1158/0008-5472.CAN-04-1443 10.1016/S0021-9258(19)49853-0 |
ContentType | Journal Article |
Copyright | Springer Science+Business Media B.V. 2009 2009 INIST-CNRS |
Copyright_xml | – notice: Springer Science+Business Media B.V. 2009 – notice: 2009 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QO 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FR3 FYUFA GHDGH K9. M0S M1P P64 PQEST PQQKQ PQUKI 7X8 |
DOI | 10.1007/s10456-009-9151-7 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Biotechnology Research Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Technology Research Database ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library Biotechnology Research Abstracts ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Engineering Research Database ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Technology Research Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1573-7209 |
EndPage | 296 |
ExternalDocumentID | 1867169271 10_1007_s10456_009_9151_7 19544081 21997401 |
Genre | Journal Article |
GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 1SB 203 23M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5VS 67N 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAFGU AAHNG AAIAL AAJKR AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACSNA ACTTH ACVWB ACWMK ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFGCZ AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ ITM IWAJR IXC IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAK LLZTM M1P M4Y MA- N2Q NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM OVD P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOR QOS R89 R9I RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S27 S3A S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z87 ZMTXR ZOVNA ~A9 H13 IQODW AAJBT AASML ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU CGR CUY CVF ECM EIF NPM AACDK AAYXX ALIPV CITATION 7QO 7XB 8FD 8FK FR3 K9. P64 PQEST PQUKI 7X8 |
ID | FETCH-LOGICAL-c466t-da0ad407613ecdb833b5f18d45f643022e7357ec900d2fa230873f4c7a8e27e53 |
IEDL.DBID | AGYKE |
ISSN | 0969-6970 |
IngestDate | Fri Aug 16 22:43:37 EDT 2024 Fri Sep 13 09:39:59 EDT 2024 Thu Sep 12 18:00:42 EDT 2024 Thu May 23 23:13:59 EDT 2024 Sun Oct 22 16:07:33 EDT 2023 Sat Dec 16 12:01:10 EST 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Vascular endothelial growth factor receptor-2 Tryosine kinase inhibitor Anti-angiogenesis Angiogenesis Growth factor receptor Enzyme Transferases Oral administration Cardiovascular disease Protein-tyrosine kinase Biological activity |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c466t-da0ad407613ecdb833b5f18d45f643022e7357ec900d2fa230873f4c7a8e27e53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 19544081 |
PQID | 211476131 |
PQPubID | 42475 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_734061727 proquest_journals_211476131 crossref_primary_10_1007_s10456_009_9151_7 pubmed_primary_19544081 pascalfrancis_primary_21997401 springer_journals_10_1007_s10456_009_9151_7 |
PublicationCentury | 2000 |
PublicationDate | 2009-09-01 |
PublicationDateYYYYMMDD | 2009-09-01 |
PublicationDate_xml | – month: 09 year: 2009 text: 2009-09-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Dordrecht |
PublicationPlace_xml | – name: Dordrecht – name: Germany |
PublicationTitle | Angiogenesis (London) |
PublicationTitleAbbrev | Angiogenesis |
PublicationTitleAlternate | Angiogenesis |
PublicationYear | 2009 |
Publisher | Springer Netherlands Springer Springer Nature B.V |
Publisher_xml | – name: Springer Netherlands – name: Springer – name: Springer Nature B.V |
References | Liu, Earl, Baban (CR9) 1995; 217 Holmes, Roberts, Thomas, Cross (CR29) 2007; 19 Folkman, Shing (CR6) 1992; 267 Gerber, McMurtrey, Kowalski (CR33) 1998; 273 Gille, Kowalski, Li (CR24) 2001; 276 Wilhelm, Carter, Tang (CR16) 2004; 64 Carmeliet, Jain (CR2) 2000; 407 Drevs, Hofmann, Hugenschmidt (CR12) 2000; 60 Folkman (CR1) 1995; 1 Goldstein, Gray, Zarrinkar (CR17) 2008; 7 Stein, Flaherty (CR23) 2007; 13 Ferrara (CR7) 1999; 77 Kenyon, Voest, Chen (CR19) 1996; 37 Zhang, Yang, Gray (CR30) 2009; 9 Ferrara, Henzel (CR5) 1989; 161 Wedge, Ogilvie, Dukes (CR15) 2000; 60 Okada, Rak, Croix (CR32) 1998; 95 Fong, Shawver, Sun (CR14) 1999; 59 Viloria-Petit, Crombet, Jothy (CR31) 2001; 61 Senger, Perruzzi, Feder, Dvorak (CR4) 1986; 46 Rousseau, Houle, Kotanides (CR27) 2000; 275 Emanuel, Gruninger, Fuentes-Pesquera (CR13) 2004; 66 Meyer, Clauss, Lepple-Wienhues (CR25) 1999; 18 Zeng, Sanyal, Mukhopadhyay (CR26) 2001; 276 Cohen, Gootenberg, Keegan, Pazdur (CR22) 2007; 12 LaMontagne, Littlewood-Evans, Schnell (CR18) 2006; 66 Kitamura, Itoh, Noda, Matsuura, Wakabayashi (CR34) 2004; 109 Hurwitz, Fehrenbacher, Novotny (CR35) 2004; 350 Takahashi, Kitadai, Bucana, Cleary, Ellis (CR11) 1995; 55 Millauer, Wizigmann-Voos, Schnurch (CR8) 1993; 72 Ferrara, Gerber, LeCouter (CR3) 2003; 9 Folkman (CR10) 1972; 175 Schueneman, Himmelfarb, Geng (CR20) 2003; 63 Yang, Edelmann, Fan (CR21) 1997; 277 Roskoski (CR28) 2008; 375 MN Stein (9151_CR23) 2007; 13 J Zhang (9151_CR30) 2009; 9 F Okada (9151_CR32) 1998; 95 N Ferrara (9151_CR3) 2003; 9 H Gille (9151_CR24) 2001; 276 J Drevs (9151_CR12) 2000; 60 H Hurwitz (9151_CR35) 2004; 350 J Folkman (9151_CR6) 1992; 267 K LaMontagne (9151_CR18) 2006; 66 S Emanuel (9151_CR13) 2004; 66 MH Cohen (9151_CR22) 2007; 12 N Ferrara (9151_CR5) 1989; 161 N Ferrara (9151_CR7) 1999; 77 HP Gerber (9151_CR33) 1998; 273 BM Kenyon (9151_CR19) 1996; 37 S Rousseau (9151_CR27) 2000; 275 K Holmes (9151_CR29) 2007; 19 DM Goldstein (9151_CR17) 2008; 7 B Millauer (9151_CR8) 1993; 72 J Folkman (9151_CR1) 1995; 1 A Viloria-Petit (9151_CR31) 2001; 61 J Folkman (9151_CR10) 1972; 175 AJ Schueneman (9151_CR20) 2003; 63 SR Wedge (9151_CR15) 2000; 60 K Yang (9151_CR21) 1997; 277 M Meyer (9151_CR25) 1999; 18 TA Fong (9151_CR14) 1999; 59 DR Senger (9151_CR4) 1986; 46 B Liu (9151_CR9) 1995; 217 P Carmeliet (9151_CR2) 2000; 407 Y Takahashi (9151_CR11) 1995; 55 SM Wilhelm (9151_CR16) 2004; 64 R Roskoski Jr (9151_CR28) 2008; 375 T Kitamura (9151_CR34) 2004; 109 H Zeng (9151_CR26) 2001; 276 |
References_xml | – volume: 375 start-page: 287 year: 2008 end-page: 291 ident: CR28 article-title: VEGF receptor protein-tyrosine kinases: structure and regulation publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.07.121 contributor: fullname: Roskoski – volume: 63 start-page: 4009 year: 2003 end-page: 4016 ident: CR20 article-title: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models publication-title: Cancer Res contributor: fullname: Geng – volume: 13 start-page: 3765 year: 2007 end-page: 3770 ident: CR23 article-title: CCR drug updates: sorafenib and sunitinib in renal cell carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2844 contributor: fullname: Flaherty – volume: 7 start-page: 391 year: 2008 end-page: 397 ident: CR17 article-title: High-throughput kinase profiling as a platform for drug discovery publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2541 contributor: fullname: Zarrinkar – volume: 19 start-page: 2003 year: 2007 end-page: 2012 ident: CR29 article-title: Vascular endothial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition publication-title: Cell Signal doi: 10.1016/j.cellsig.2007.05.013 contributor: fullname: Cross – volume: 175 start-page: 409 year: 1972 end-page: 416 ident: CR10 article-title: Anti-angiogenesis: new concept for therapy of solid tumors publication-title: Ann Surg doi: 10.1097/00000658-197203000-00014 contributor: fullname: Folkman – volume: 66 start-page: 635 year: 2004 end-page: 647 ident: CR13 article-title: A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models publication-title: Mol Pharmacol doi: 10.1124/mol.104.000638 contributor: fullname: Fuentes-Pesquera – volume: 217 start-page: 721 year: 1995 end-page: 727 ident: CR9 article-title: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1995.2832 contributor: fullname: Baban – volume: 1 start-page: 27 year: 1995 end-page: 31 ident: CR1 article-title: Angiogenesis in cancer, vascular, rheumatoid and other disease publication-title: Nat Med doi: 10.1038/nm0195-27 contributor: fullname: Folkman – volume: 9 start-page: 669 year: 2003 end-page: 676 ident: CR3 article-title: The biology of VEGF and its receptors publication-title: Nat Med doi: 10.1038/nm0603-669 contributor: fullname: LeCouter – volume: 109 start-page: 576 year: 2004 end-page: 580 ident: CR34 article-title: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice publication-title: Int J Cancer doi: 10.1002/ijc.20012 contributor: fullname: Wakabayashi – volume: 277 start-page: 245 year: 1997 end-page: 254 ident: CR21 article-title: A mouse model of human familial adenomatous polyposis publication-title: J Exp Zool doi: 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.0.CO;2-O contributor: fullname: Fan – volume: 66 start-page: 221 year: 2006 end-page: 231 ident: CR18 article-title: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2001 contributor: fullname: Schnell – volume: 59 start-page: 99 year: 1999 end-page: 106 ident: CR14 article-title: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types publication-title: Cancer Res contributor: fullname: Sun – volume: 72 start-page: 835 year: 1993 end-page: 846 ident: CR8 article-title: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis publication-title: Cell doi: 10.1016/0092-8674(93)90573-9 contributor: fullname: Schnurch – volume: 12 start-page: 713 year: 2007 end-page: 718 ident: CR22 article-title: FDA drug approval summary: bevacizumab (Bevacizumab) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer publication-title: Oncologist doi: 10.1634/theoncologist.12-6-713 contributor: fullname: Pazdur – volume: 350 start-page: 2335 year: 2004 end-page: 2342 ident: CR35 article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa032691 contributor: fullname: Novotny – volume: 161 start-page: 851 year: 1989 end-page: 858 ident: CR5 article-title: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells publication-title: Biochem Biophys Res Commun doi: 10.1016/0006-291X(89)92678-8 contributor: fullname: Henzel – volume: 55 start-page: 3964 year: 1995 end-page: 3968 ident: CR11 article-title: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer publication-title: Cancer Res contributor: fullname: Ellis – volume: 60 start-page: 970 year: 2000 end-page: 975 ident: CR15 article-title: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy publication-title: Cancer Res contributor: fullname: Dukes – volume: 37 start-page: 1625 year: 1996 end-page: 1632 ident: CR19 article-title: A model of angiogenesis in the mouse cornea publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Chen – volume: 95 start-page: 3609 year: 1998 end-page: 3614 ident: CR32 article-title: Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.7.3609 contributor: fullname: Croix – volume: 275 start-page: 10661 year: 2000 end-page: 10672 ident: CR27 article-title: Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase publication-title: J Biol Chem doi: 10.1074/jbc.275.14.10661 contributor: fullname: Kotanides – volume: 60 start-page: 4819 year: 2000 end-page: 4824 ident: CR12 article-title: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model publication-title: Cancer Res contributor: fullname: Hugenschmidt – volume: 61 start-page: 5090 year: 2001 end-page: 5101 ident: CR31 article-title: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis publication-title: Cancer Res contributor: fullname: Jothy – volume: 276 start-page: 3222 year: 2001 end-page: 3230 ident: CR24 article-title: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants publication-title: J Biol Chem doi: 10.1074/jbc.M002016200 contributor: fullname: Li – volume: 276 start-page: 32714 year: 2001 end-page: 32719 ident: CR26 article-title: Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively publication-title: J Biol Chem doi: 10.1074/jbc.M103130200 contributor: fullname: Mukhopadhyay – volume: 407 start-page: 249 year: 2000 end-page: 257 ident: CR2 article-title: Angiogenesis in cancer and other diseases publication-title: Nature doi: 10.1038/35025220 contributor: fullname: Jain – volume: 46 start-page: 5629 year: 1986 end-page: 5632 ident: CR4 article-title: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines publication-title: Cancer Res contributor: fullname: Dvorak – volume: 273 start-page: 30336 year: 1998 end-page: 30343 ident: CR33 article-title: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation publication-title: J Biol Chem doi: 10.1074/jbc.273.46.30336 contributor: fullname: Kowalski – volume: 9 start-page: 28 year: 2009 end-page: 39 ident: CR30 article-title: Targeting cancer with small molecule kinase inhibitors publication-title: Nat Rev Cancer doi: 10.1038/nrc2559 contributor: fullname: Gray – volume: 77 start-page: 527 year: 1999 end-page: 543 ident: CR7 article-title: Molecular and biological properties of vascular endothelial growth factor publication-title: J Mol Med doi: 10.1007/s001099900019 contributor: fullname: Ferrara – volume: 18 start-page: 363 year: 1999 end-page: 374 ident: CR25 article-title: A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases publication-title: EMBO J doi: 10.1093/emboj/18.2.363 contributor: fullname: Lepple-Wienhues – volume: 267 start-page: 10931 year: 1992 end-page: 10934 ident: CR6 article-title: Angiogenesis publication-title: J Biol Chem contributor: fullname: Shing – volume: 64 start-page: 7099 year: 2004 end-page: 7109 ident: CR16 article-title: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-1443 contributor: fullname: Tang – volume: 276 start-page: 3222 year: 2001 ident: 9151_CR24 publication-title: J Biol Chem doi: 10.1074/jbc.M002016200 contributor: fullname: H Gille – volume: 217 start-page: 721 year: 1995 ident: 9151_CR9 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1995.2832 contributor: fullname: B Liu – volume: 350 start-page: 2335 year: 2004 ident: 9151_CR35 publication-title: N Engl J Med doi: 10.1056/NEJMoa032691 contributor: fullname: H Hurwitz – volume: 13 start-page: 3765 year: 2007 ident: 9151_CR23 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2844 contributor: fullname: MN Stein – volume: 7 start-page: 391 year: 2008 ident: 9151_CR17 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2541 contributor: fullname: DM Goldstein – volume: 161 start-page: 851 year: 1989 ident: 9151_CR5 publication-title: Biochem Biophys Res Commun doi: 10.1016/0006-291X(89)92678-8 contributor: fullname: N Ferrara – volume: 19 start-page: 2003 year: 2007 ident: 9151_CR29 publication-title: Cell Signal doi: 10.1016/j.cellsig.2007.05.013 contributor: fullname: K Holmes – volume: 109 start-page: 576 year: 2004 ident: 9151_CR34 publication-title: Int J Cancer doi: 10.1002/ijc.20012 contributor: fullname: T Kitamura – volume: 175 start-page: 409 year: 1972 ident: 9151_CR10 publication-title: Ann Surg doi: 10.1097/00000658-197203000-00014 contributor: fullname: J Folkman – volume: 66 start-page: 221 year: 2006 ident: 9151_CR18 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2001 contributor: fullname: K LaMontagne – volume: 407 start-page: 249 year: 2000 ident: 9151_CR2 publication-title: Nature doi: 10.1038/35025220 contributor: fullname: P Carmeliet – volume: 46 start-page: 5629 year: 1986 ident: 9151_CR4 publication-title: Cancer Res contributor: fullname: DR Senger – volume: 18 start-page: 363 year: 1999 ident: 9151_CR25 publication-title: EMBO J doi: 10.1093/emboj/18.2.363 contributor: fullname: M Meyer – volume: 61 start-page: 5090 year: 2001 ident: 9151_CR31 publication-title: Cancer Res contributor: fullname: A Viloria-Petit – volume: 277 start-page: 245 year: 1997 ident: 9151_CR21 publication-title: J Exp Zool doi: 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.0.CO;2-O contributor: fullname: K Yang – volume: 64 start-page: 7099 year: 2004 ident: 9151_CR16 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-1443 contributor: fullname: SM Wilhelm – volume: 55 start-page: 3964 year: 1995 ident: 9151_CR11 publication-title: Cancer Res contributor: fullname: Y Takahashi – volume: 60 start-page: 4819 year: 2000 ident: 9151_CR12 publication-title: Cancer Res contributor: fullname: J Drevs – volume: 1 start-page: 27 year: 1995 ident: 9151_CR1 publication-title: Nat Med doi: 10.1038/nm0195-27 contributor: fullname: J Folkman – volume: 275 start-page: 10661 year: 2000 ident: 9151_CR27 publication-title: J Biol Chem doi: 10.1074/jbc.275.14.10661 contributor: fullname: S Rousseau – volume: 77 start-page: 527 year: 1999 ident: 9151_CR7 publication-title: J Mol Med doi: 10.1007/s001099900019 contributor: fullname: N Ferrara – volume: 59 start-page: 99 year: 1999 ident: 9151_CR14 publication-title: Cancer Res contributor: fullname: TA Fong – volume: 72 start-page: 835 year: 1993 ident: 9151_CR8 publication-title: Cell doi: 10.1016/0092-8674(93)90573-9 contributor: fullname: B Millauer – volume: 95 start-page: 3609 year: 1998 ident: 9151_CR32 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.7.3609 contributor: fullname: F Okada – volume: 267 start-page: 10931 year: 1992 ident: 9151_CR6 publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)49853-0 contributor: fullname: J Folkman – volume: 37 start-page: 1625 year: 1996 ident: 9151_CR19 publication-title: Invest Ophthalmol Vis Sci contributor: fullname: BM Kenyon – volume: 63 start-page: 4009 year: 2003 ident: 9151_CR20 publication-title: Cancer Res contributor: fullname: AJ Schueneman – volume: 9 start-page: 28 year: 2009 ident: 9151_CR30 publication-title: Nat Rev Cancer doi: 10.1038/nrc2559 contributor: fullname: J Zhang – volume: 273 start-page: 30336 year: 1998 ident: 9151_CR33 publication-title: J Biol Chem doi: 10.1074/jbc.273.46.30336 contributor: fullname: HP Gerber – volume: 9 start-page: 669 year: 2003 ident: 9151_CR3 publication-title: Nat Med doi: 10.1038/nm0603-669 contributor: fullname: N Ferrara – volume: 375 start-page: 287 year: 2008 ident: 9151_CR28 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.07.121 contributor: fullname: R Roskoski Jr – volume: 60 start-page: 970 year: 2000 ident: 9151_CR15 publication-title: Cancer Res contributor: fullname: SR Wedge – volume: 66 start-page: 635 year: 2004 ident: 9151_CR13 publication-title: Mol Pharmacol doi: 10.1124/mol.104.000638 contributor: fullname: S Emanuel – volume: 276 start-page: 32714 year: 2001 ident: 9151_CR26 publication-title: J Biol Chem doi: 10.1074/jbc.M103130200 contributor: fullname: H Zeng – volume: 12 start-page: 713 year: 2007 ident: 9151_CR22 publication-title: Oncologist doi: 10.1634/theoncologist.12-6-713 contributor: fullname: MH Cohen |
SSID | ssj0009684 |
Score | 1.975474 |
Snippet | Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish... |
SourceID | proquest crossref pubmed pascalfrancis springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 287 |
SubjectTerms | Administration, Oral Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - pharmacology Animals Biological and medical sciences Biomedical and Life Sciences Biomedicine Blood and lymphatic vessels Blood vessels and receptors Cancer Research Cardiology Cardiology. Vascular system Cell Biology Cell Movement - drug effects Cells, Cultured Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Endothelial Cells - drug effects Endothelial Cells - physiology Female Fundamental and applied biological sciences. Psychology HCT116 Cells Humans Medical sciences Mice Mice, Inbred C57BL Mice, Nude Mice, Transgenic Models, Biological Neoplasms - drug therapy Neoplasms - pathology Oncology Ophthalmology Original Paper Oximes - administration & dosage Oximes - pharmacology Phenylurea Compounds - administration & dosage Phenylurea Compounds - pharmacology Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - pharmacology Substrate Specificity Vascular Endothelial Growth Factor A - pharmacology Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors Vertebrates: cardiovascular system Xenograft Model Antitumor Assays |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF6VVkJIFSotUNNSzQFxgK4Se22vfUJp1VIhtUKISr1Zu95dYhFsU7uV8lP4t8z4kajicXISx8kmM9755vkx9ibQDjFbYrnTwnC0xxFPpZryXIdGKiWtMRTQv7yKL67DTzfRzQb7OPbCUFnluCd2G7WpcoqRT9BRCdHlFv5EaQoC5O3kQ_2TE30UpVkHLo1HbCvwQ8rXbp2cXX3-sp6_G3fkw3hMeZzKVYKz76JDFMEpS5Ci_ePygYnarlWD_5braS7-hkP_yKF2pul8hz0dMCXMeiV4xjZsucv2ZiX60z-W8Ba6Ks8ufL7LHl8OyfQ99msGNKx4sYSmI8PBfe8YqGEfX9FFpe5VsaDGqmMYy1XBloY6thaotPANHfh2Dj1hD-DGaWt8wANol_iz8Bvge1GijYSinBe6oDfNVQN1hSi9BeqnINoKPAt4vK1AlaZ_cl89Z9fnZ19PL_jA1MDzMI5bbtRUmZBCIsLmRidC6Mj5iQkjh4gHYYKVIpI2T6dTEzgV0BhC4cJcqsQG0kbiBdssq9LuM9ASHajURC5C4CGMr7VFkOVik0rtJ0577N0onKzuB3Jk69HLJMkMJZmRJDPpsaMH4ltdEVB9DbqWHjsY5ZkNN2-TrVTNY7A6i3cdpVJUaau7JpMi7LGfx172WrBeTBoRizde_H5Ui_VH_3Olr_67kAP2pM9iUW3bIdtsb-_sawRDrT4aFP03hCkJSw priority: 102 providerName: ProQuest |
Title | A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo |
URI | https://link.springer.com/article/10.1007/s10456-009-9151-7 https://www.ncbi.nlm.nih.gov/pubmed/19544081 https://www.proquest.com/docview/211476131/abstract/ https://search.proquest.com/docview/734061727 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLa2TkJIiMvGpQwqPyAeYK7aJI6Tx4A6JtAmhKhUniI7tteoxamadKj8E_4t5yRNy7TxsCcnduJcfOzz-VwJeeMpC5gtMswqXzPgx5zFQg5YpgItpBRGaxTon1-EZ-Pg84RP9oi3FV24Wb_VSNYL9T--bsDrGcryY-BSTOyTA45ZqTvkIPn048toF2o3rPMMQxmzMBZbXeZtnVzjRg8WsoQfY5uMFrdBzhvq0poLnT5qPAPLOnghGp_M-qtK9bPfN0M73uEDH5OHG1BKk4aKnpA94w7JUeJgQ_5zTd_S2ky0lr8fknvnG238EfmTUIx2PF_Tss6mAwvnCUWPf6hReSGvZD5Hz6wT2tq7UuM0unzNgerp5bL4VU1pk_GHwsprFnDAPFqt4WfBE-gsd8Bkae6mucrxoqks6aIAmF9RdMjAvBfQSqFcFlQ63ZxcFU_J-HT0_eMZ26R6YFkQhhXTciB1gDIV32RaRb6vuB1GOuAWIBPgDCN8LkwWDwbas9LDOIa-DTIhI-MJw_1npOMKZ14QqgTswGLNLQfk4uuhUgZQmg11LNQwsqpL3rVDni6aiB7pLnYzjkEKY5DiGKSiS3rXiGJ7h4cGOrA37ZLjlkrSzewvoXEY4KdAK922wrRFXYx0pliVqfCDBjx2yfOGtnYvE3NMAw43v28JZdf1f9_05Z2uPib3G7UYGsu9Ip1quTKvAV1Vqkf2xUT0NpMKyg-ji6_foHbsJX8BWlwgjA |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,31755,33779,33780,41116,41558,42185,42627,43345,43840,52146,52269,74102,74659 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BkaASQtBCMYUyB8QBuiLxrr32CUWIKkDTUyvlZu16dxuLYJvarZSfwr9lxnYSVTxOjuPXJjPe-Wbn8TH2JjQeMVviuDfCcrTHEU-VHvHcSKu0Vs5aWtCfncXTC_l1Hs2H3JxmSKtcz4ndRG2rnNbIP6CjItHlFuOP9U9OpFEUXB0YNO6ye1IISRl9aq62PXfjjnAYtymPU7UJavaVc4gcOEUGUrR5XN0ySw9r3eA_5Htqi79hzz_ipp05OnnMHg04Eia94J-wO67cY_uTEn3oHyt4C11mZ7dkvsfuz4YA-j77NQFqULxcQdMR4OBcdwxUpI_fmKLSN7pYUjHVMaxTVMGVlqq0lqiocIlOe7uAnqQHcLJ0NX7gIbQr_Fn4BPhelGgXoSgXhSnopIVuoK4QmbdANRREVYFHAbdXFejS9js31VN2cfL5_NOUD-wMPJdx3HKrR9pKWgYRLrcmEcJEfpxYGXlEOQgNnBKRcnk6GtnQ65BaDwovc6UTFyoXiWdsp6xK95yBUeg0pTbyEYINYcfGOARWPrapMuPEm4C9Wwsnq_smHNm23TJJMkNJZiTJTAXs6Jb4NleElFOD7mTADtfyzIYXtsk26hUw2BzFN43CJ7p01XWTKSF7vBewg14LtoNJI2Luxovfr9Vie-t_jvTFfwfymj2Yns9Os9MvZ98O2W4fxaLctpdsp726dq8QDLXmqFP53_wmBxg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BkSokhErLw7SUOSAO0FUdr-21TyiiROXRigOVcrN2vbvEItimdivlp_BvmfEjUUXh5Dh-bTLjnW92Hh9jrwLtELMlljstDEd7HPFUKp_nOjRSKWmNoQX9s_P49CL8NI_mQ0uhZkirHOfEbqI2VU5r5MfoqITocovJsRuyIr6ezN7VvzgRSFGgdWDTuMvuoZH0icxAzuWm_27ckQ_jNuVxKtcBzr6KDlEEpyhBivaPyxsm6kGtGvy3XE9zcRsO_SuG2pmm2Q57OGBKmPZK8IjdseUu25uW6E__XMFr6LI8u-XzXbZ9NgTT99jvKVCz4uUKmo4MB-e9I6CCffxGF5W6VsWSCquOYExXBVsaqthaotLCd3Tg2wX0hD2AE6et8QMPoF3hz8InwI-iRBsJRbkodEEnLVQDdYUovQWqpyDaCjwKuL2sQJWm37muHrOL2Ydv70_5wNTA8zCOW26Ur0xISyLC5kYnQujITRITRg4RD8IEK0UkbZ76vgmcCqgNoXBhLlViA2kj8YRtlVVpnzHQEh2o1EQuQuAhzERriyDLxSaVepI47bE3o3Cyum_IkW1aL5MkM5RkRpLMpMcOb4hvfUVA-TXoWnpsf5RnNry8TbZWNY_B-ii-dRRKUaWtrppMirDHfh572mvBZjBpRCzeePHbUS02t_7nSJ__dyAv2TZqe_bl4_nnfXa_D2hRmtsB22ovr-wLxEWtPuw0_g9LnwtE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+highly+selective%2C+orally+bioavailable%2C+vascular+endothelial+growth+factor+receptor-2+tyrosine+kinase+inhibitor+has+potent+activity+in+vitro+and+in+vivo&rft.jtitle=Angiogenesis+%28London%29&rft.au=LaMontagne%2C+Kenneth+R.&rft.au=Butler%2C+Jeannene&rft.au=Borowski%2C+Virna+B.&rft.au=Fuentes-Pesquera%2C+Angel+R.&rft.date=2009-09-01&rft.issn=0969-6970&rft.eissn=1573-7209&rft.volume=12&rft.issue=3&rft.spage=287&rft.epage=296&rft_id=info:doi/10.1007%2Fs10456-009-9151-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s10456_009_9151_7 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0969-6970&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0969-6970&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0969-6970&client=summon |